MedTrace Logo

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

NCT02777242 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2018-03-22

Study results available
· View outcomes & findings →

Summary

Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.

Conditions

  • Hypogonadism

Interventions

COMBINATION_PRODUCT

Testosterone enanthate auto-injector

SC injections of QST 50 mg or 75 mg or 100 mg

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Jed Kaminetsky, MD · Manhattan Medical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02777242 on ClinicalTrials.gov